WO2003051312A3 - E2f and cancer therapy - Google Patents

E2f and cancer therapy Download PDF

Info

Publication number
WO2003051312A3
WO2003051312A3 PCT/US2002/040355 US0240355W WO03051312A3 WO 2003051312 A3 WO2003051312 A3 WO 2003051312A3 US 0240355 W US0240355 W US 0240355W WO 03051312 A3 WO03051312 A3 WO 03051312A3
Authority
WO
WIPO (PCT)
Prior art keywords
provides
hhhrslh
peptide
derivative
effective amount
Prior art date
Application number
PCT/US2002/040355
Other languages
French (fr)
Other versions
WO2003051312A2 (en
Inventor
Alex Laon Scarborough
Debabrata Banerjee
Joseph R Bertino
Original Assignee
Sloan Kettering Inst Cancer
Alex Laon Scarborough
Debabrata Banerjee
Joseph R Bertino
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer, Alex Laon Scarborough, Debabrata Banerjee, Joseph R Bertino filed Critical Sloan Kettering Inst Cancer
Priority to AU2002366364A priority Critical patent/AU2002366364A1/en
Publication of WO2003051312A2 publication Critical patent/WO2003051312A2/en
Publication of WO2003051312A3 publication Critical patent/WO2003051312A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides a composition for inhibiting tumor cell growth comprising effective amount of the peptide HHHRSLH or derivative thereof. This invention provides a composition comprising an amount of the peptide HHHRSLH or derivative thereof effective to inhibit the activity of transcription factor E2F. This invention provides a method for inhibiting tumor cell growth comprising contacting cells with effective amount of the peptide HHHRSLH or derivative thereof. This invention provides a method for inhibiting tumor growth comprising contacting cells with effective amount to inhibit the activity of transcription factor E2F. This invention provides a method of inhibiting tumor cell growth in a subject comprising administering to the subject and effective amount of the peptide HHHRSLH or derivative thereof.
PCT/US2002/040355 2001-12-18 2002-12-17 E2f and cancer therapy WO2003051312A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002366364A AU2002366364A1 (en) 2001-12-18 2002-12-17 E2f and cancer therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34190801P 2001-12-18 2001-12-18
US60/341,908 2001-12-18

Publications (2)

Publication Number Publication Date
WO2003051312A2 WO2003051312A2 (en) 2003-06-26
WO2003051312A3 true WO2003051312A3 (en) 2003-10-30

Family

ID=23339510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/040355 WO2003051312A2 (en) 2001-12-18 2002-12-17 E2f and cancer therapy

Country Status (2)

Country Link
AU (1) AU2002366364A1 (en)
WO (1) WO2003051312A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
WO2010120931A2 (en) 2009-04-14 2010-10-21 University Of Medicine And Dentistry Of New Jersey E2f as a target for treatment of hormone refractory prostate cancer
US9880150B2 (en) 2015-01-28 2018-01-30 Thomas Jefferson University E2F reporter melanoma cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IKEDA M.: "A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation", PROC. NATL. ACAD. SCI. USA, vol. 93, April 1996 (1996-04-01), pages 3215 - 3220, XP002966991 *

Also Published As

Publication number Publication date
AU2002366364A8 (en) 2003-06-30
WO2003051312A2 (en) 2003-06-26
AU2002366364A1 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
AU2003267203A1 (en) Method for administering thermotherapy to prevent the growth of tumors
WO2001030381A3 (en) Use of csf-1 inhibitors
WO2007067682A3 (en) In vivo cell surface engineering
WO2002002563A3 (en) Substituted-triazolopyrimidines as anticancer agents
EP1201639A3 (en) Lipoxin compounds and their use in treating cell proliferative disorders
AU2003302892A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003059942A3 (en) Peptides and peptidomimetics having anti-proliferative activity and their use
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
AU2003226676A1 (en) Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
WO2004046309A3 (en) Methods for inhibiting viral replication in vivo
WO2002102306A3 (en) Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
AU3052799A (en) Pharmaceutical compositions comprising erythropoietin for treatment of cancer
EP0772625A4 (en) Oligonucleoside compounds and methods for inhibiting tumor growth, invasion and metastasis
MXPA05010575A (en) Peptabody for cancer treatment.
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
WO2006113579A3 (en) Tumor inhibition by modulating sprouty expression or activity
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
WO2000067762A3 (en) Selenium-containing pro-drugs for cancer therapy
WO2000047231A3 (en) Novel antisense inhibition of rad51
AU2002342808A1 (en) Extract with anti-tumor and anti-poisonous activity
WO2003051312A3 (en) E2f and cancer therapy
WO2005032595A3 (en) Methods and compositions for the inhibition of stat5 in prostate cancer cells
AU2003273250A1 (en) Triazaspiro compounds useful for treating or preventing pain
WO2001035995A3 (en) Tr3-specific binding agents and methods for their use
WO2005094282A3 (en) Combination therapy comprising cloretazinetm

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP